VALEO overview

Valeo Pharma Announces Additional Provincial Reimbursement Coverage for Redesca™ and Redesca HP™ PR Newswire MONTREAL, July 13, 2021 Redesca™ and Redesca HP™ now covered for public reimbursement in 7 provinces and territories across Canada Private payer health plan coverage in Canada now at 70% MONTREAL , July 13, 2021 /PRNewswire/ - Valeo Pharma Inc . (CSE:VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, announced today that Redesca™...

ioneer Ltd's (ASX:INR) (OTCMKTS:GSCCF) Bernard Rowe caught up with Proactive's Andrew Scott soon after announcing they've signed their first binding ......

Valeo Pharma to Report Second Quarter 2021 Results and Hold Investors Conference Call / Webcast PR Newswire MONTREAL, June 23, 2021 MONTREAL , June 23, 2021 /PRNewswire/ - Valeo Pharma Inc . (CSE:VPH) (OTCQB: VPHIF) (FSE:VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the second quarter ended April 30, 2021 on Tuesday June 29, 2021 after market close. Valeo will host a conference call to discuss...

Valeo Pharma (CSE: VPH – OTCQB: VPHIF) CEO Steve Saviuk joined Steve Darling from Proactive to share news the company has started the ......

Valeo Pharma Announces Commercial Launch of Enerzair® Breezhaler® and Atectura® Breezhaler® PR Newswire MONTREAL, June 22, 2021 Product shipments have commenced across Canada National respiratory sales force recruitment well advanced, field deployment on-going Private and public reimbursement coverage progressing Nelly Komari , joins Valeo as Senior Vice President Scientific & Medical Affairs MONTREAL , June 22, 2021 /PRNewswire/ - Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("...

Datametrex AI Limited (TSXV:DM) (OTCQB:DTMXF) CEO Marshall Gunter tells Proactive the Toronto, Canada-based artificial intelligence mining company has ......

Valeo Pharma Provides Update on Private Payer Reimbursement for Enerzair® Breezhaler® and Atectura® Breezhaler® PR Newswire MONTREAL, June 1, 2021 Private payer health plan coverage in Canada for Enerzair Breezhaler and Atectura Breezhaler has reached 80% Reimbursement proceedings with publicly funded health plans ready to commence MONTREAL , June 1, 2021 /PRNewswire/ - Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company,...

Valeo Pharma Projecting Record Revenues for Second Quarter 2021 PR Newswire MONTREAL, May 26, 2021 Record revenues and margins expected for Q2-21 Redesca® launch beginning to impact financial performance Respiratory sales force infrastructure well advanced in support of coming Enerzair® Breezhaler® and Atectura® Breezhaler® commercial launch MONTREAL , May 26, 2021 /PRNewswire/ - Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian...

Valeo Pharma (CSE: VPH-OTCQB: VPHIF) CEO Steve Saviuk joined Steve Darling from Proactive to bring news the Ontario Public Drug Program has said they ......

Valeo Pharma's Redesca® and Redesca HP® to Be Covered Under the Ontario Public Drug Benefit Program PR Newswire MONTREAL, April 28, 2021 Ontario represents 37% of the Canadian low molecular weight heparin market Additional provincial coverage expected to follow MONTREAL , April 28, 2021 /PRNewswire/ - Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, today announced that it has entered into a Product Listing Agreement...

Valeo Pharma Upsizes And Closes $6.6 Million Non-Brokered Private Placement PR Newswire MONTRÉAL, April 27, 2021 Valeo insiders participation of $2.6 million MONTRÉAL, April 27, 2021 /PRNewswire/ - Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it has upsized and closed a $6.645 million non-brokered private placement of unsecured non-convertible debenture units (the "Private Placement"). The Company...

Valeo Pharma Announces Commercial Launch of Redesca™ and Redesca HP™ PR Newswire MONTREAL, April 15, 2021 Shipments have commenced across Canada National sales coverage in full deployment through a dedicated key account managers team Private and public reimbursement activities on target. MONTREAL , April 15, 2021 /PRNewswire/ - Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, announced today that it has commenced...

Valeo Pharma Completes Negotiations with Pan-Canadian Pharmaceutical Alliance for Redesca® and Redesca HP® PR Newswire MONTREAL, April 6, 2021 MONTREAL , April 6, 2021 /PRNewswire/ - Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian specialty pharmaceutical company, today announced that it has completed its negotiations and entered into a letter of intent ("LOI") with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding Redesca® and...

Valeo Pharma Inc. Enters into an Agreement for Enerzair® Breezhaler® and Atectura® Breezhaler® in Canada PR Newswire MONTREAL, March 29, 2021 Valeo to commercialize Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® , 2 innovative asthma therapies approved by Health Canada Positions Valeo as one of the leading Canadian Respiratory companies Almost 4 million Canadians afflicted with asthma 1 ; Canadian market for asthma medication exceeds $700M annually 2 MONTREAL , March 29, 2021...

Valeo Pharma's Hesperco™ Capsules at the Core of Montreal Heart Institute's Hesperidin Coronavirus Clinical Trial PR Newswire MONTREAL, Feb. 17, 2021 Montreal Heart Institute study to evaluate the ability of hesperidin, the medicinal ingredient in Hesperco™ capsules, to reduce the severity of symptoms and the need for hospitalization in COVID-19 patients Hesperidin interferes / inhibits 2 key proteins of SARS-CoV-2 necessary for entry and infection of cells, suggesting that hesperidin may...